Ophthalmology · San Francisco, CA
NPI
1750469359
Since 2006
Specialty
Ophthalmology
Code 207W00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
2200 Ofarrell St
San Francisco, CA, 94115
Phone (415) 833-2000
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$74K
1,901 prescriptions
Company payments, 2025
$251
From 2 companies
Medicare prescription drug claims, 2024
In 2024, the drug Kenneth C Ip prescribed most often to Medicare patients was Latanoprost, with 565 prescriptions and refills. In total Kenneth C Ip wrote 1,901 Medicare prescriptions that cost $74K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-13.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Latanoprost Generic | 565 | 1,602 | 206 | $8,088 |
| Prednisolone Acetate Generic | 357 | 514 | 199 | $19K |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 289 | 865 | 89 | $6,776 |
| Timolol Maleate Generic | 204 | 633 | 75 | $3,905 |
| Brimonidine Tartrate Generic | 187 | 537 | 70 | $3,056 |
| Diclofenac Sodium Generic | 70 | 71 | 34 | $1,002 |
| Dorzolamide Hcl Generic | 46 | 140 | 16 | $1,141 |
| Cyclosporine Generic | 36 | 64 | Under 11 | $5,717 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 20 | 20 | 13 | $246 |
| Brinzolamide Generic | 17 | 42 | Under 11 | $4,560 |
| Moxifloxacin Moxifloxacin Hcl | 12 | 12 | Under 11 | $137 |
| Nevanac Nepafenac | 12 | 15 | Under 11 | $10K |
Brand drugs: 439 claims; generic drugs: 1,462 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kenneth C Ip $251 ($251 in general payments such as food, travel and fees) from 2 companies. The largest payer was Alcon Vision LLC with $203.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.